We develop new
treatments for central
nervous system disorders.

We develop new
treatments for central
nervous system disorders.

Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate

– Long-term safety data collected in pediatric patients treated with investigational drug ecopipam; durable treatment effect reported with no evidence of tachyphylaxis –  CHICAGO, October 5, 2023 – An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the ... Read more
Read More

Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome

– Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe –  CHICAGO, March 1, 2023 – Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of ... Read more
Read More

Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics

– Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placebo –  CHICAGO—January 11, 2023 – A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the total number of ... Read more
Read More

Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults.  To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Latest News

  • Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

  • For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

  • At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

  • We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate

– Long-term safety data collected in pediatric patients treated with investigational drug ecopipam; durable treatment effect reported with no evidence of tachyphylaxis –  CHICAGO, October 5, 2023 – An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the ... Read more
Read More

Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults.  To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.

OUR COMMITMENT

Emalex Biosciences

CLINICAL TRIALS

Drug Pipeline

DRUG PIPELINE

Partnerships

PARTNERSHIPS

Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?

For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.

At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.

We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate

– Long-term safety data collected in pediatric patients treated with investigational drug ecopipam; durable treatment effect reported with no evidence of tachyphylaxis –  CHICAGO, October 5, 2023 – An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the ... Read more
Read More

Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome

– Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe –  CHICAGO, March 1, 2023 – Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of ... Read more
Read More